Atlas Trials

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

Clinical trial NCT04368728 · COMPLETED

Trial details

NCT number
NCT04368728
Sponsor
BioNTech SE
Status
COMPLETED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
SARS-CoV-2 InfectionCOVID-19
Start date
2020-04-29
Primary completion
2023-02-10
Enrollment
46969

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.